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ABSTRACT
Background: The average five-year survival for non-small cell lung cancer 
(NSCLC) patients is approximately 15%. Emerging evidence indicates that microRNAs 
(miRNAs) constitute a new class of gene regulators in humans that may play an 
important role in tumorigenesis. Hence, there is growing interest in studying their 
role as possible new biomarkers whose expression is aberrant in cancer. Therefore, 
in this study we identified dysregulated miRNAs by next generation sequencing (NGS) 
and analyzed their prognostic value.
Methods: Sequencing by oligo ligation detection technology was used to identify 
dysregulated miRNAs in a training cohort comprising paired tumor/normal tissue 
samples (N = 32). We validated 22 randomly selected differentially-expressed miRNAs 
by quantitative real time PCR in tumor and adjacent normal tissue samples (N = 178). 
Kaplan-Meier survival analysis and Cox regression were used in multivariate analysis 
to identify independent prognostic biomarkers. 
Results: NGS analysis revealed that 39 miRNAs were dysregulated in NSCLC: 28 
were upregulated and 11 were downregulated. Twenty-two miRNAs were validated 
in an independent cohort. Interestingly, the group of patients with high expression of 
both miRNAs (miR-21high and miR-188high) showed shorter relapse-free survival (RFS) 
and overall survival (OS) times. Multivariate analysis confirmed that this combined 
signature  is an independent prognostic marker for RFS and OS (p = 0.001 and p < 
0.0001, respectively).
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INTRODUCTION
Lung cancer is the leading cause of death from 
cancer worldwide, with an incidence of more than a 
million of cases annually [1]. Even though outcomes 
for patients at all lung cancer stages have improved in 
recent years, its survival rate remains very poor [2, 3]. 
Surgery is the only potentially curative treatment for 
early-stage non-small cell lung cancer (NSCLC) patients. 
However, there are also many cases that remain uncured 
following surgery. In fact, 30% to 55% of patients with 
NSCLC relapse and die from their disease despite curative 
resection [4, 5]. Hence, there is an urgent need for new 
biomarkers for this disease which can be used in clinical 
practice, and accordingly, more studies are also required to 
identify and validate these new prognostic and diagnostic 
biomarkers in lung cancer [6-8].
MicroRNAs (miRNAs) are a class of small highly-
conserved, non-coding RNAs that were discovered in the 
early 1990s, and are approximately 18-25 nucleotides 
long [9-12]. These molecules are important post-
transcriptional gene expression regulators related to 
fundamental processes such as cellular proliferation, 
differentiation, development, and apoptosis [13]. Altered 
miRNA levels have been described in several pathologies, 
including cancer [14-17], and several different studies 
have suggested that miRNAs could be useful as diagnostic 
and prognostic biomarkers in lung cancer [18-20]. 
Additionally, microRNAs have also involved in resistance 
to chemotherapy and novel targeted agents in non-small 
cell lung cancer [21]. Furthermore, emerging technologies 
such as next generation sequencing (NGS) have shown 
great potential as a platform for small RNA analysis 
and its use is now being extended to find novel cancer 
biomarkers.
Therefore, in the context of the above, the aim of 
this study was to analyze the miRNAome using NGS 
to characterize dysregulated miRNAs in a large cohort 
of resectable NSCLC patients, in order to establish 
expression profiles associated with prognosis in this 
disease, thus allowing patients with highest risk of relapse 
to be distinguished. 
RESULTS
The main clinicopathological characteristics of the 
training (N = 32 patients) and validation (N = 178 patients) 
sets including age, gender, stage of disease, and histology 
are summarized in Table 1. The median follow-up was 
81.2 [0.5-110] and 81.2 [1-113] months for training and 
validation sets, respectively. 
Differential microRNA expression by NGS
Annotation analyses of small RNA biotypes 
revealed that 88.62% of the small RNAs found were 
miRNAs. Furthermore, when miRNA annotation was 
analysed, 940 mature miRNAs had expression in one 
sample at least. Differential expression analysis was 
performed to this universe of 940 miRNAs. Analysis of 
principal components revealed to have two differentiated 
sample groups in our training cohort corresponding to 
tumoral and normal samples. 
39 miRNAs were dysregulated in tumor 
compared to normal samples: 28 were upregulated and 
11 downregulated (Table 2). However, differentially-
expressed miRNAs were not found when we compared 
these data with clinicopathological variables. Supervised 
hierarchical clustering analysis of these differentially-
expressed miRNAs revealed two groups of accurately-
defined samples (normal and tumor tissues) according to 
their miRNA expression profile (Figure 1). 
Functional analyses
In silico functional studies, based on computational 
analyses from 39 miRNA found dysregulated in this 
study, showed several biological processes (bp) of GO 
terms significantly related to lung, such as, respiratory 
system development, lung development, respiratory 
tube development, which seems to indicate that these 
differentially expressed miRNAs could be tissue specific. 
Furthermore, response to growth factor stimulus and 
cellular response to growth factor stimulus GO terms 
were found enriched in this analysis. This fact is in 
concordance with the increase in cellular growth during 
carcinogenesis (Table 3). In addition, functional analyses 
were performed with the prognostic value miRNAs (miR-
21 and miR-188), where target gene enrichments were 
carry out. Analyses showed an elevated number of target 
genes for both miRNAs related to essential pathways in 
carcinogenesis process (Supplemental Figure 1). 
MicroRNA expression validation
From the 39 differentially-expressed miRNAs, 
seven presented an average of fewer than 30 counts and 
so were excluded from the validation analysis. Twenty-
two miRNAs were randomly selected for validation in an 
independent cohort of patients (N = 178). The Wilcoxon 
signed-rank test, confirmed that there were statistically 
Conclusions: NGS technology can specifically identify dysregulated miRNA profiles 
in resectable NSCLC samples. MiR-21 or miR-188 overexpression correlated with a 
negative prognosis, and their combined signature may represent a new independent 
prognostic biomarker for RFS and OS.
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significant differences in the expression of these miRNAs 
between tumor and normal adjacent lung tissue with the 
exception of miR-125a (Table 2A-2B).
Prognostic value of microRNAs
Of the 22 miRNAs analyzed, only miR-21-5p and 
miR-188-5p had any prognostic value: higher expression 
of these miRNAs was significantly correlated with shorter 
RFS (24.03 vs. 56.83 months, p = 0.042 and 23.67 vs. 
66.97 months, p = 0.009, respectively) and OS (42.60 vs. 
82.60 months, p = 0.043 and 42.90 vs. 81.23 months, p = 
0.002, respectively) (Table 4, Figure 2A-2B). According to 
these results, and in order to better assess the prognosis of 
patients, we also considered the combination of these two 
microRNAs. Interestingly, patients with high expression 
of both miRNAs (miR-21high and miR-188high) had shorter 
RFS and OS times (p = 0.006 and p = 0.0006, respectively) 
(Table 4, Figure 2C). 
Multivariate Cox regression analysis
To determine which analyzed variables had an 
independent impact on the lung cancer prognosis in our 
cohort, we performed multivariate analysis. The Clinical 
and experimental variables included were all those that 
were statistically significant in the univariate analysis. 
KRAS status was an independent prognostic variable for 
RFS according to the Cox regression model (p = 0.020) 
and the signature (miR-21high and miR-188high) was an 
independent poor prognostic biomarker for RFS (p = 
0.001) and OS (p < 0.0001) (Table 4). 
Prognostic signature validation
Data from TCGA for squamous lung cancer 
(LUSC) and lung adenocarcinoma (LUAD) patients was 
used for in silico validation of the miRNA signature. 
Figure 1: Supervised hierarchical clustering analysis of differentially-expressed miRNAs. The level of miRNA expression 
is color-coded by intensity: white squares represents lower miRNA expression and red squares higher expression in tumor tissue compared 
with adjacent normal tissue
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Clinicopathological characteristics of these patients are 
summarized in Table 1. The analyses confirmed that both 
miR-21 and miR-188 were significantly overexpressed 
in tumor tissues (p < 0.0001). Patients with post-surgical 
complications were excluded from the survival analysis, 
and only those patients who had at least 1 month of follow 
up were included (N = 496). Analysis revealed a poor 
prognosis for OS in patients with high levels of miR-21 
(37.86 vs 59.66 months, p = 0.020) (Figure 2D); however 
miR-188 did not show prognostic value in the group of 
TCGA patients. RFS analysis was not carried out as the 
data for disease status was not specified in many of the 
patients.
DISCUSSION
MicroRNAs have been shown to play an important 
role in the tumorigenesis and development of NSCLC. 
However, few studies characterize the profiles of miRNAs 
in paired tumor and adjacent normal tissue samples at the 
same time. In our study, the microRNAome was assessed 
in a large cohort (training set = 32 and validation set = 
178, respectively) of resectable NSCLC patients, who 
long-term follow-ups were available, thus strengthening 
the analysis. Additionally, this study presents the useful 
application of deep next generation sequencing technology 
for profiling miRNAs in resectable lung tumor specimens. 
Some similar studies have been performed using different 
microarray platforms [22, 23], ours being one of the first to 
Table 1: Clinicopathological characteristics of the patients
Training set Validation set In silico set
N= 32 % N=178 % N=618 %
Age at surgery (median, range): 64 [47-82] 65 [26-85] 68 [38-88]
Gender
Male 26 81.2 154 85.5 352 56.9
Female 6 18.8 24 13.5 266 43.1
Stage (a)
I 17 53.1 105 59 350 56.6
II 6 18.8 35 19.7 178 28.8
IIIA 9 28.1 38 21.3 90 14.6
Histology
SCC 13 40.6 84 47.2 279 45.1
ADC 19 59.4 74 41.6 339 54.9
Others 20 11.2
Performance Status
0 22 68.8 118 66.3 NS NS1-2 10 31.2 60 33.7
Differentiation grade
Poor 10 31.2 43 24.2
NS NSModerate 12 37.5 77 43.2Well 7 21.9 31 17.4
NS 3 9.4 27 15.2
Smoking Status
Current 16 50 86 48.3
NS NSFormer 8 25 72 40.5
Never 8 25 20 11.2
Relapse
No 20 62.5 98 55.1 373 60.4
Yes 12 37.5 80 44.9 33 5.3
NS 212 34.3
Dead
No 19 59.4 102 57.3 462 74.8
Yes 13 40.6 76 42.7 156 25.2
ADC, adenocarcinoma; SCC, squamous cell carcinoma; NS, non-specified.
(a) According to the American Joint Committee on Cancer staging manual (TNM 6).
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Name stat FC p-value p-adj§ p-value
miR-96 4.750 5,85 0 0
miR-182* 3.921 3,70 0 0.009 <0.001
miR-200b 3.882 2,56 0 0.010
miR-132 3.830 2,08 0 0.011
miR-629 3.671 2,31 0 0.019
miR-29a* 3.624 2,30 0 0.020 <0.001
miR-19b-1* 3.615 2,10 0 0.020 <0.001
miR-34a* 3.499 2,20 0 0.026 <0.001
miR-616 3.465 1,83 0.001 0.026
miR-339* 3.394 2,26 0.001 0.029 <0.001
miR-4536 3.389 4,00 0.001 0.029
miR-590* 3.376 2,12 0.001 0.029 <0.001
miR-200c 3.375 2,93 0.001 0.029
miR-31* 3.366 8,99 0.001 0.029 <0.001
miR-3194 3.360 3,45 0.001 0.029
miR-188* 3.340 2,54 0.001 0.030 <0.001
miR-21* 3.301 4,85 0.001 0.034 <0.001
miR-450a 3.243 2,42 0.001 0.039
miR-579 3.235 4,37 0.001 0.039
miR-135b* 3.206 6,63 0.001 0.042 <0.001
miR-199b* 3.180 2,05 0.001 0.043 <0.001
miR-25 3.164 4,34 0.002 0.043
miR-224 3.160 5,59 0.002 0.043 <0.001
miR-141 3.158 2,72 0.002 0.043
miR-22 3.153 1,84 0.002 0.043
miR-4791 3.115 7,24 0.002 0.046
miR-2116 3.108 4,11 0.002 0.046
miR-196b* 3.055 7,03 0.002 0.050 <0.001
B) MicroRNAs downregulated
NGS   RTqPCR
Name stat FC p-value p-adj§ p-value
miR-1247 -3.144 -2,89 0.002 0.043
miR-451a* -3.466 -3,43 0.001 0.026 <0.001
miR-144* -3.494 -2,84 0 0.026 <0.001
miR-516b-1 -3.535 -43,319 0 0.025
miR-195* -3.927 -1,57 0 0.009 0.039
miR-125a* -4.392 -1,78 0 0.002 0.679
miR-218* -4.467 -2,06 0 0.001 <0.001
miR-145* -4.778 -1,89 0 0 0.001
miR-30a* -5.141 -2,81 0 0 <0.001
miR-126* -5.795 -2,75 0 0 <0.001
miR-139* -6.477 -2,93 0 0 <0.001
A) MicroRNAs upregulated and B) MicroRNAs downregulated.
FC, fold change
§ p-adj calculated with FDR method
*miRNAs validated by RTqPCR.
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analyze dysregulated miRNAs in fresh frozen tumor and 
adjacent normal samples of a large cohort of characterized 
NSCLC patients using SOLiD technology. 
NGS technology allows the whole microRNAome 
of each sample to be analyzed with high sensitivity, a 
wide dynamic range, high accuracy, and extraordinary 
technical reproducibility [24, 25]. In the cancer research 
context, NGS technology is especially useful compared 
to other methodologies because it allows the detection of 
miRNAs not yet described [24, 26, 27]. However, there 
are some limitations in using NGS, including its high cost 
and the large amounts of data it produces. Nonetheless, 
the development of new platforms using barcodes, are 
now becoming available. This allow several samples to be 
multiplexed into a single run [28], and is contributing to 
a continuing cost reduction and new bioinformatics tools 
for analyzing and interpreting these complex data sets [27, 
29]. 
Of the 39 dysregulated miRNAs in the training 
set, 22 miRNAs were validated using RTqPCR, which is 
considered one of the gold standard techniques for gene 
expression analyses due to its sensitivity and robustness 
requiring minimal amounts of RNA [30-32]. Functional 
analyses of these dysregulated miRNAs shown an 
enrichment of several biological processes related to lung 
specifically, such as, respiratory system development, lung 
development, respiratory tube development, which seem 
to indicate that these differentially expressed miRNAs 
could be tissue specific. Interestingly, other biological 
processes, related to cellular response to growth factor 
stimulus were found enriched in this analysis as well. This 
fact is in concordance with an increased growth cell in 
carcinogenesis process.
Regarding the analyzed miRNAs, the 
overexpression of miR-182, miR-31, miR135b, miR-
199b, miR-224 and miR-196b and miR-34a have been 
detected in both the training and validation set. Extensive 
profiling studies have connected dysregulated levels of 
miR-182 with several cancer types, including NSCLC 
[33]. Furthermore, miR-182 may function as an oncogenic 
miRNA to enhance cancer cell proliferation, survival, 
aggressiveness, tumorigenesis, and drug resistance [34-
36]. Some targets of miR-182 are involved in repaired 
DNA [37] and others are tumor suppressor genes such as 
PTEN and TP53 (miRTarBase data). A meta-analysis in 
various cancers has shown the overexpression of miR-
31 [38], which was overexpressed in early stages, and 
expression was high in tumor progression and reached 
higher levels in advanced stages. MiR-31 has been shown 
to act as an oncogenic miRNA by targeting specific 
tumor suppressors, including the large tumor suppressor 
2 (LATS2) and PP2A regulatory subunit B alpha isoform 
(PPP2R2A) [39]. An analysis of the predicted targets of 
miR-31 found a relationship between this miRNAs and 
the initiation, progression and treatment response of 
lung cancer through the cell cycle, the cytochrome P450 
pathway, metabolic pathways, apoptosis, the chemokine 
signaling pathway, and the MAPK signaling pathway [40].
A few studies have described miR-135b and its 
relationship in NSCLC, but only Lin et al. have found 
Table 3: Gene-Ontology terms dysregulated by differentially expressed miRNA. 
N lor pval padj pat GO
GO:0007517 306 0,258453 9,59E-06 0,031571 1 muscle organ development
GO:0060541 151 0,34596 2,75E-05 0,031571 1 respiratory system development
GO:0070848 498 0,191793 3,24E-05 0,031571 1 response to growth factor stimulus
GO:0071363 489 0,1885 5,12E-05 0,031571 1 cellular response to growth factor stimulus
GO:0030324 131 0,358327 5,18E-05 0,031571 1 lung development
GO:0008543 150 0,336667 5,42E-05 0,031571 1 fibroblast growth factor receptor signaling pathway
GO:0061061 406 0,204676 5,69E-05 0,031571 1 muscle structure development
GO:0030323 134 0,348344 6,87E-05 0,033321 1 respiratory tube development
GO:0050767 336 0,215493 0,000109 0,040653 1 regulation of neurogenesis
GO:0048015 148 0,320334 0,000126 0,040653 1 phosphatidylinositol-mediated signaling
GO:0048017 148 0,320334 0,000126 0,040653 1 inositol lipid-mediated signaling
GO:0044087 296 0,226529 0,000128 0,040653 1 regulation of cellular component biogenesis
GO:1901698 468 0,180575 0,000137 0,040653 1 response to nitrogen compound
GO:0010243 441 0,184938 0,000147 0,040653 1 response to organonitrogen compound
GO:0035295 381 0,197236 0,000164 0,042486 1 tube development
GO:0030510 56 0,502461 0,000201 0,045892 1 regulation of BMP signaling pathway
GO:0033238 42 -0,55751 0,000193 0,045892 -1 regulation of cellular amine metabolic process
N, number of genes; lor,  Log Odds Ratio; pval, p-value; padj, p-value adjusted by multiple test method; pat, pathway; GO, 
Gene onthology term (biological process).
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Figure 2: Kaplan-Meier curves for overall survival (OS) and relapse-free survival (RFS) according to miRNA 
expression for patients with resected non-small cell lung cancer (NSCLC). Panels A and B show OS and RFS for miR-21-
5p and miR-188-5p, respectively in the validation set. Panel C shows the significant correlation between the combined variable, high 
expression of both miRNAs (miR-21high and miR-188high), with shorter OS and RFS times in validation set. Panel D shows OS and RFS 
for miR-21 in the in silico set. Continuous variables were dichotomized as high (≥ median) and low (< median), using the median relative 
expression of each gene as a cutoff. Statistics were calculated using the log-rank test, and the significance was set at p < 0.05.
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upregulated miR-135b in invasive NSCLC cells [41]. 
Other studies in different cancer types have found 
an overexpression in miR-135b [42, 43]. MiR-135b 
expression enhances cancer cell invasive and migratory 
abilities in vitro and promotes cancer metastasis in vivo by 
targeting multiple key components on the Hippo pathway, 
including LATS2, BTRCP and NDR2, as well as LZTS1 
[41]. Regarding miR-224, some studies in the same type 
[44] and different types of cancer support our results 
[45, 46]. MiR-224 functions as an oncogene in NSCLC 
by directly targeting TNFAIP1 and SMAD4. Caspase 3 
(CASP3) and caspase 7 (CASP7) are targets of miR-224 
in NSCLC, and miR-224 partly promotes lung cancer cells 
proliferation and migration by directly targeting CASP7 
and downregulating its expression; miR-224 attenuates 
TNF-α induced apoptosis by directly targeting CASP3, 
which results in a reduced cleaved parp1 expression in 
lung cancer cells and suggests a oncogenic role for miR-
224 in lung cancer pathogenesis [47]. Two studies in 
lung cancer tissues and lung adenocarcinomas support 
our data about miR-196b [48, 49]. The same results have 
been found in different cancer types [50]. HOXA9 has 
been suggested to act as a target of miR-196b by playing 
a central role in controlling the aggressive behavior of 
lung cancer cells [49]. Unexpectedly, miR-34a was found 
upregulated in the training and validation set. MiR-34a has 
been reported to be down-regulated in NSCLC [51] other 
cancer types and to work as tumor suppressor miRNA. 
Considering all these results, more studies need to be 
performed in more extended cohorts of patients to be able 
to better understand the function of miR-34a in NSCLC.
The down-regulation of miR-451a, miR-144, miR-
195, miR-218, miR-145, miR-30a, miR-126 and miR-139 
has been found in both the training and validation set. Two 
meta-analyses in NSCLC have demonstrated the reduced 
expression of these eight miRNAs in tumor [52, 53]. AKT 
and oncogene MYC have been described as targets, and 
a role of miR-451a in the carcinogenesis process has 
been shown [54]. The met proto-oncogene (MET), which 
is often amplified in human cancers and functions as an 
important regulator of cell growth and tumor invasion, has 
been identified as a direct target of miR-144 [55]. MiR-195 
overexpression inhibits ACHN cell viability, migration, 
and invasion, and also induces cell apoptosis by targeting 
VEGFR2 via the PI3K/AKT and Raf/MEK/ERK signaling 
pathways, which indicates that miR-195 plays a tumor 
suppressive role [56]. Studies in vitro have shown an anti-
cancer function of miR-218, and the down-expression of 
miR-218 increases myocyte enhancer factor 2D (MEF2D) 
levels by promoting lung cancer growth [57], and by 
inhibiting NSCLC proliferation and metastasis via by 
downregulating CDCP1 [58]. The down-regulation of 
miR-218 increases epithelial-mesenchymal transition and 
tumor metastasis in lung cancer by targeting Slug/ZEB2 
signaling [59]. In vitro analyses have shown a tumor 
suppressor role of miR-145, where miR-145 inhibits TGF-
β-induced epithelial-mesenchymal transition and invasion 
through the repression of SMAD3 and TGFBR2 in NSCLC 
cells [60, 61]. Besides, miR-145 inhibits the migration 
and invasion of lung cancer cells via fascin homolog 1 
(FSCN1) downregulation [62] and cell growth is inhibited 
by miR-145, while MYC has been shown to be a direct 
target for miR-145 [63]. MiR-30a overexpression in lung 
tumor culture cells inhibits migration and cell invasion, 
and partially attributes to lower EYA2 expression [64] and 
influences NSCLC progression through the PI3K/AKT 
signaling pathway by targeting IGF1R [65]. MiR-126 is 
known to play a critical role in the angiogenesis process 
Table 4: Univariate (log-rank test) and multivariate (Cox regression model) analyses for RFS and OS
Univariate Multivariate
RFS OS RFS OS
Variable Median (months) p
§ Median 
(months) p












































48.33 0.029 -- -- -- -- -- -- -- --
§ p-value was calculated using the log-rank test. * p-values with Bonferroni corrections are shown in parentheses. CI, 
confidence interval; HR, hazard ratio; NR, not-reached; OS, overall survival; RFS, relapse-free survival.
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[17, 66]. Furthermore in vitro analyses have shown that 
miR-126 overexpression in the NSCLC line cell inhibits 
cell growth through different gene targets, including CRK, 
EGFL7 and PIK3R2 [67-69]. Dysregulated miR-139 
expression has been reported in some human tumor types. 
Analyses in vitro and in vivo have demonstrated miR-139-
5p suppressed tumor growth and directly targeted MET, 
which could be a possible mechanism by which miR-139-
5p regulates growth and the metastatic potential [70]. 
Other miRNAs such as miR-29a, miR-199-5p, miR-
339-5p, miR-590-5p and miR-19b-1 are overexpressed 
in both the training and validation set, but have barely 
been described in cancer in general and in NSCLC in 
particular. Only one study in lung adenocarcinoma has 
identified miR-29a overexpression in a paired-sample 
analysis (tumor and normal from the same patients) [71]. 
Regarding miR-199-5p, only one study in lung cancer and 
miRNA changes related to asbestos has reported the same 
results [72]. MiR-339-5p overexpression has been reported 
in a study performed in the peripheral blood of 100 
individuals which included 86 patients with predominantly 
early-stage NSCLC and 24 healthy donors [73]. MiR-590-
5p overexpression has not been reported in NSCLC, but 
studies support our findings in other cancer types [74, 
75]. Although miR-19b-1 is not widely described in the 
literature, miR-19b overexpression was validated in our 
validation cohort. To support this finding, miR-19b-1 
upregulation has been observed in HeLa human cancer 
cells and in mice lung tumors [76], but no similar study to 
ours is currently available which detects deregulation in 
this miRNA. For this reason, more studies are needed to 
better understand the relationship between these miRNAs 
and the carcinogenesis process of NSCLC.
In agreement with our findings, miR-21 has been 
reported to be overexpressed in several solid malignancies 
[77-79], including lung cancer [80, 81] where several 
studies in paired tumor and adjacent normal tissue 
samples in NSCLC showed similar results [18, 71, 82]. 
Interestingly, different meta-analysis studies performed 
in many tumor types [83, 84] and which only considered 
NSCLC [52, 53] confirm this finding. Therefore, in silico 
analyses have shown that miR-21 has large number of 
genes targets and many of them are directly involved 
in essential pathways dysregulated in the tumorigenesis 
process. 
The analysis of the prognostic value of dysregulated 
miRNAs show that higher relative expression of miR-21 
and miR-188 is associated with worse outcome in our 
cohort of resectable NSCLC. These data agreed with the 
in silico study performed on data obtained from the TCGA 
cohort, confirming the overexpression of both miRNAs in 
tumor samples compared to normal lung tissues. In the 
TCGA set, patients with higher expression of miR-21 
exhibited shorter OS (37.86 vs 59.66 months, p = 0.020). 
In line with these results, some studies have reported that 
high levels of miR-21 in either tumor or blood samples 
were associated with a negative prognosis in lung 
cancer patients [15, 83, 85, 86]. Interestingly, Seike et 
al. described that aberrant miR-21 expression; enhanced 
by the activated EGFR signaling pathway, played a 
significant role in lung carcinogenesis in those that never-
smoked [82]. Mechanistically, it has been described 
that overexpression of miR-21 leads to the inhibition of 
several tumor suppressor genes, such as PTEN, TPM1 
and PDCD4 [87]. Thus, miR-21 seems to be a promising 
biomarker and is also an interesting therapeutic target 
whose inhibition may have benefits in NSCLC patients. 
Recently, a preclinical study in a murine lung cancer 
model with an anti-miR-21 molecule revealed that treated 
animals displayed tumor regression or no tumor growth 
and prolonged survival while compared with the untreated 
group [88].
Our results obtained in the validation set by 
RTqPCR also indicated that patients with elevated miR-
188 expression in tumor tissue had a shorter RFS (p = 
0.009) and OS (p = 0.002). However, these findings could 
not be confirmed by in silico analysis in the TCGA cohort 
due to probably technical (pair tumor/normal analysis, 
NGS vs RTqPCR) and biological (amount of miRNA) 
differences. Several interpretations can explain this 
results. Initially, miRNA data expression of patients in our 
validation cohort was analyzed using RTqPCR while the 
TCGA validation cohort samples were analyzed by NGS. 
The different sensitivity between these two techniques 
could explain, in part, these different results. Otherwise, 
a distinct concept to calculate relative expression could 
have influence over them too. In validation set, the 
relative miRNA expression was calculated as the number 
of times the tumor tissue expression was higher or lower 
compared to its paired-normal tissue for each patient (fold-
change) whereas the relative expression of TCGA data 
was calculated by RPKM. Despite the miRNA profiling 
techniques have vastly improved in the last years, there 
are still differences in performance and platform-specific 
biases that can impact the generated output [28]. Finally, 
the expression levels of miR-21 were high in normal and 
tumor samples, due to its constitutive expression, which 
is frequently upregulated in solid tumours. Therefore, the 
range RPKM values between high and low normalized was 
wide, so when dichotomization is performed, patients with 
higher or lower values from median are clearly defined and 
Kaplan-Meier analysis shown two well differentiated and 
significative populations of patients with a clearly different 
prognosis. In contrast, the expression levels of miR-188 
were very low in normal and even in tumor samples. 
Consequently, the ranges between normalized values were 
narrow, so when dichotomization is performed, patients 
with higher or lower values from median were not clearly 
differentiated and Kaplan-Meier differences found were 
not significative. This can explain why miR-188 cannot 
find a prognosis value in TCGA cohort. 
There are limited studies analyzing the prognostic 
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role of miR-188 in cancer [89-91], and in fact none has 
been found in lung cancer to date. In concordance with 
our results, in patients with acute myeloid leukemia 
(cytogenetically-normal), high miR-188 expression 
has been significantly associated with shorter OS and 
event-free survival [89]. Although the computational 
analysis has shown a relationship of miR-188 with the 
carcinogenesis process, further studies are still needed to 
clarify the function of this miRNA in carcinogenesis and 
its prognostic implication in cancer. 
Finally, we identified a patient subgroup defined 
by a combined higher expression levels of miR-21 and 
miR-188 that exhibited poor outcome and resulted in an 
independent prognostic factor for RFS (HR: 0.485 [0.313-
0.753]; p = 0.001) and OS (HR 0.389 [0.237-0.638]; p < 
0.0001) in multivariate analysis, suggesting its potential 
role as biomarker useful for distinguishing patients which 
could benefit from more exhaustive monitoring.
In summary, the miRNA signature identified in this 
work may provide new biomarkers for providing early 
prognoses in NSCLC patients as well as being potentially 
useful as a therapeutic target for this disease in the near 
future.
CONCLUSIONS
This study revealed that the NGS system can 
accurately detect miRNAs and specifically identify 
dysregulated miRNAs in resectable NSCLC samples; 
furthermore, these results were validated in a large 
independent cohort of patients. Survival analyses showed 
that miR-21-5p or miR-188-5p overexpression were 
negative prognostic factors, implicating miR-188 in 
NSCLC for the first time. Furthermore, the combined 
signature of these two miRNAs was significantly 
associated with shorter RFS and OS times and was 
confirmed by a multivariate analysis as an independent 
prognostic marker, representing a potential novel negative 
prognostic biomarker for NSCLC. However, especially 
considering that the role of miR-188 in NSCLC remains 
unclear, further studies must be performed in diverse 
populations and using functional evaluation methods 
in order to confirm and extend our findings. Given that, 
to date, very few studies have used paired fresh frozen-
tissues, and it would be interesting to extend this study 
in NSCLC, using a greater number of samples, as well 
as in other tumor types. We consider our findings to be 
important in both translational clinical research and in the 
development of novel miRNA-based cancer therapies. 
MATERIALS AND METHODS
Patients and tissue samples
This retrospective study included 32 patients in 
the training set, and 178 patients in the validation set 
with NSCLC from the Consorcio Hospital General 
Universitario de Valencia who underwent surgery between 
2004 and 2013, and who fit the eligibility criteria: resected, 
non-pretreated stage I to IIIA patients (according to the 
American Joint Committee on Cancer staging manual) 
with a histological diagnosis of NSCLC. Tumor and 
adjacent normal lung specimens were obtained by surgical 
resection and were preserved in RNA-later at -80º C until 
analysis (Applied Biosystems, USA). The study was 
conducted in accordance with the Declaration of Helsinki, 
and the institutional ethical review board approved the 
protocol. Relapse-free survival (RFS) was estimated as 
the time from surgery to recurrence or death from the 
disease, whereas overall survival (OS) was defined as the 
time from diagnosis to the date of death or the patient’s 
last follow-up. In silico validation set included data from 
618 resectable NSCLC caucasian patients from the TCGA 
project.
RNA isolation and quality evaluation
Total RNA isolation from the tumor and normal 
fresh frozen tissues was performed using TRI Reagent 
(Sigma, USA) according to the manufacturer’s 
instructions. RNA samples were subjected to quality 
control before carrying out NGS; using RNA Nano 
and Small RNA Chips on an Agilent 2100 Bioanalyzer 
(Agilent technologies, Germany). The miRNA fraction 
was enriched with an optimal profile using a PureLink 
miRNA isolation kit (Invitrogen, USA). After performing 
quality control, 32 of the tested samples had an optimal 
quality profile for NGS sequencing. 
NGS
Small RNA sequencing using a sample barcode-
identification multiplex with SOLiD (Sequencing by 
Oligo Ligation Detection) technology was performed. A 
SOLiD total RNA-seq kit was used to prepare small RNA 
libraries and templated beads were subsequently prepared 
according to the manufacturer’s instructions. Briefly, the 
libraries were constructed and the cDNAs amplified with 
the 3’ PCR primers supplied in the SOLiD RNA barcoding 
kit containing the P2 sequence required for emulsion PCR 
(ePCR) using beads. After ePCR and bead enrichment, the 
samples were deposited onto a slide and sequenced on the 
SOLiDTM 4 System (Applied Biosystems, USA).
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RTqPCR
The expression of 22 randomly-selected miRNAs 
was validated in an independent cohort using miRNA-
specific TaqMan assays (Applied Biosystems). Briefly, 
reverse transcription (RT) was performed with 500 
ng of total RNA using a TaqMan MicroRNA reverse 
transcription kit (Applied Biosystems) following the 
multiplex RT protocol, according to the manufacturer’s 
instructions. Normalization and relative expression 
quantification was calculated with miR-16 using the 
comparative Cq method (2-(Cq sample-Cq control)) to validate the 
miRNA expression and used the Pfaffl formula to perform 
survival analysis.
Bioinformatic analysis
In the training set, color space fasta (csfasta) and 
quality (qual) format input data were grouped for each 
sample and transformed into FASTQ files in order to 
import them into the CLC Genomics Workbench software 
(version 5.5.2; CLC bio, Denmark). The trimming 
and count were performed together to remove adapter 
sequences and to count different tags. The miRNAs were 
subsequently annotated using the miRBase platform 
(release 20.0, Homo sapiens) and the Ensembl.org or 
tRNAscan-SE databases for other small RNA biotypes. 
Reads for the same mature miRNAs were grouped and 
normalized by totals, reads per kilobase per million 
mapped reads (RPKM). Principal components analysis 
was performed to visualize the sample grouping and the 
Baggerley test was used to analyze differential miRNA 
expression between tumor and normal tissues and the FDR 
(false discovery rate) was used to adjust p-values. 
Functional analyses were carried out using a 
new bioinformatics algorithm [92] with differentially 
dysregulated miRNAs, applying statistics and p-values 
obtained from Baggerley test.
In silico validation was performed using two lung 
cancer data sets from the TCGA consortium [93, 94]. 
Clinical and miRNA-seq (Illumina HiSeq platform) 
information was directly downloaded from the ICGC 
Data Portal [95], https://dcc.icgc.org/releases/current/
projects/LUAD-US, and https://dcc.icgc.org/releases/
current/projects/LUSC-US. MiR-21-5p and miR-188-
5p RPKM values were extracted using their genomic 
positions, obtained from miRBase. T-tests paired (p1, 
only cases with paired tumor and normal samples, N = 71) 
and non-paired (p2, comparison of all tumor samples vs 
all normal samples) were carried out  on log-transformed 
expression values to analyse  differential expression, using 
R statistical environment [96]. Analyses were considered 
to be statistically significant to p-value ≤ 0.05.
Statistical analysis
Mann-Whitney and Chi-square tests were applied 
to confirm that there were not statistically significant 
differences in clinicopathological characteristics between 
both, training and validation sets. The Wilcoxon matched-
pairs test was used to validate NGS results tested by 
RTqPCR. The survival curves were plotted according 
to the univariate Kaplan-Meier method (log-rank) 
with clinicopathological variables and dichotomized 
microRNA expression levels. For multiple comparisons, 
the Bonferroni method was applied, maintaining the 
overall probability of ƙp < 0.05. Finally, a Cox model for 
multivariate analyses was used to assess the independent 
value of the tested biomarkers. Statistical analysis was 
performed using the Statistical Package for the Social 
Sciences (SPSS, USA) version 15.0. A p-value ≤ 0.05 was 
considered to be statistically significant for all analyses.
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